Francisco Trust under agreement dated February 28, 1996 sold $344K of DYAI

Dyadic (DYAI) reported $4.7M cash and short-term securities at June 30, 2026, down from $8.6M at end-2025, with $3.8M cash burn in the first half of 2026. After its Q2 report, it announced a $2.9M registered direct offering and private placement, expecting $2.28M net proceeds, plus an ATM with Craig-Hallum. The company also updated multiple partnerships and noted going-concern doubt.

Dyadic International said it raised about $2.9 million via a registered direct offering and a concurrent private placement of warrants. The company will sell 3.625 million common shares at $0.795 and issue 3.625 million warrants at $0.005 each, exercisable at $0.84. Proceeds will support general corporate uses, including R&D and working capital, with Aegis Capital as placement agent.

Dyadic International (NASDAQ: DYAI) entered into agreements on Aug. 13, 2026 for a registered direct offering and concurrent private placement. It will sell 3,625,000 shares at $0.795/share and issue warrants to buy 3,625,000 shares with a $0.84 exercise price. Gross proceeds are expected at about $2.9 million, before expenses, for general corporate purposes.

DYADIC INTERNATIONAL INC (DYAI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 DYADIC ANNOUNCES SECOND QUARTER 2026 FINANCIAL RESULTS ACCELERATING COMMERCIALIZATION MOMENTUM ACROSS KEY BUSINESS AREAS Dyadic to host earnings call on August 12 at 5:00 pm ET JUPITER, FL — August 12, 2026 — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, o

Dyadic International (NASDAQ:DYAI) said at the Lytham Partners Spring 2026 Investor Conference that it has shifted from an R&D and licensing focus to a commercial-stage protein and enzyme business. It has launched six products in 12 months and secured global distribution and partner deals, including purchase orders for transferrin. The company expects 2026 to be a launch year and reported nearly $3.5 million in upfront milestone fees from Proliant and Inzymes.

Dyadic International (NASDAQ: DYAI) said it is collaborating with Scripps Research to evaluate monoclonal antibody and vaccine candidates targeting hantaviruses, including Andes virus, associated with Hantavirus Pulmonary Syndrome. The companies plan to assess Dyadic’s C1 microbial platform for rapid, scalable biologic manufacturing, building on prior Andes work and earlier GMP/Phase 1 C1-produced biologics.